DUBLIN--(BUSINESS WIRE)--The "Radiation Dermatitis - Epidemiology Insight - 2030" report has been added to ResearchAndMarkets.com's offering.
This 'Radiation Dermatitis (RD) - Epidemiology Forecast - 2030' report delivers an in-depth understanding of and historical and forecasted epidemiology of Radiation Dermatitis in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Radiation Dermatitis Epidemiology
The RD epidemiology division provides insights about the historical and current patient pool, along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends and assumptions undertaken.
Country-wise Radiation Dermatitis Epidemiology
The epidemiology segment also provides the Radiation Dermatitis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total number of incident cases of Radiation Dermatitis associated in 7MM countries was 3,012,048 in 2020.
- As per the estimates, the United States has the largest incident population of Radiation Dermatitis.
- Among the EU5 countries, Germany had the highest incident cases of Radiation Dermatitis, followed by France. On the other hand, Spain had the lowest incident cases, with 151,518 cases in 2020.
Key Assessments
- Patient Segmentation
- Disease Risk and Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population
Geographies Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Key Topics Covered:
1 Key Insights
2 Report Introduction
3 Radiation Dermatitis Market Overview at a Glance
3.1 Market Share (%) Distribution of Radiation Dermatitis in 2018
3.2 Market Share (%) Distribution of Radiation Dermatitis in 2030
4 Executive Summary of Radiation Dermatitis
5 Disease Background and Overview
5.1 Introduction
5.2 Pathophysiology
5.3 Signs and Symptoms
5.4 Risk Factors
5.5 Types of Radiation Dermatitis (RD)
5.6 Clinical manifestations
5.7 Diagnosis
5.8 Grading
5.9 Differential Diagnosis
5.1 Treatment
5.10.1 Treatment of acute radiodermatitis
5.10.2 Treatment of chronic radiodermatitis
5.19.1 ONS Treatment Guidelines
6 Epidemiology and Patient Population
6.1 Key Findings
6.2 7MM Total Incident Population of Radiation Dermatitis
6.3 Epidemiology of Radiation Dermatitis
6.4 The United States
6.4.1 Radiotherapy Utilization in the United States
6.4.2 Incidence of Radiation Dermatitis in the United States
6.4.3 Grade-specific cases of Radiation Dermatitis in the United States
6.4.4 Treated cases of Radiation Dermatitis in the United States
6.5 EU5
6.5.1 Germany
6.5.2 France
6.5.3 Italy
6.5.4 Spain
6.5.5 United Kingdom
6.6 Japan
7 Organizations contributing towards Radiation Dermatitis
8 Patient Journey
9 Case Reports
10 Emerging Therapies
10.1 Key Cross Competition
10.2 Tempol (APC-400): Adamis Pharmaceuticals/Matrix Biomed
10.2.1 Drug Description
10.2.2 Regulatory Milestones
10.2.3 Clinical Development
10.2.4 Clinical Trials Information
10.2.5 Safety and Efficacy
10.2.6 Product Profile
10.3 BMX-001: BioMimetix JV
11 Radiation Dermatitis: Seven Major Market Analysis
13.1 Key Findings
13.2 Market Size of Radiation Dermatitis in 7MM
13.3 Market Outlook
12 KOL Views
13 Market Drivers
14 Market Barriers
15 SWOT Analysis
16 Unmet Needs
17 Market Access
18 Appendix
For more information about this report visit https://www.researchandmarkets.com/r/loq6sa
